Ongoing studies in the antithrombotic treatment of adult patients who have acute PE with or without concomitant DVT
| Setting . | Intervention . | Study design . | ClinicalTrials.gov identifier . |
|---|---|---|---|
| Massive and submassive PE | Recombinant human prourokinase vs alteplase | Phase 2a randomized | NCT03108833 |
| High and intermediate-high risk PE with emboli in the pulmonary trunk or in the main pulmonary arteries | Surgical pulmonary embolectomy vs catheter-directed thrombolysis | Randomized, phase 2, non-inferiority | NCT03218410 |
| Acute submassive PE (radiologic extension) | Thrombin-activatable fibrinolysis inhibitor (DS-1040b) | Phase 1b, single ascending dose, randomized, double-blind, placebo-controlled | NCT02923115 |
| Normotensive right ventricular dysfunction | Percutaneous mechanical thrombectomy by indigo aspiration system | Prospective, single group | NCT03218566 |
| Intrapulmonary thrombolysis by Bashir endovascular catheter | Prospective, single group | NCT03927508 | |
| Catheter-directed thrombolysis vs ultrasound-assisted thrombolysis | Randomized controlled | NCT02758574 | |
| Diuretic vs vascular filling | Randomized controlled | NCT02531581 | |
| Supplemental oxygen added to conventional anticoagulant treatment vs standard management | Randomized, open label | NCT04003116 | |
| Nitric oxide (inhaled) vs placebo | Randomized, triple blind | NCT01939301 | |
| Sildenafil + apixaban vs apixaban | Randomized, open label | NCT02946944 | |
| Isolated subsegmental PE | No anticoagulant treatment of patients with isolated subsegmental emboli and negative serial bilateral lower extremity ultrasound | Prospective cohort | NCT01455818 |
| Hemodynamically stable symptomatic PE | HESTIA vs PESI scores for acute management concerning home treatment | Randomized, open label | NCT02811237 |
| Normotensive right ventricular dysfunction and/or increased biomarkers | LMWH for 72 hours followed by dabigatran | Prospective, single-group assignment | NCT02596555 |
| Intermediate-high risk PE | Alteplase + UFH followed by apixaban vs placebo + UFH followed by apixaban | Randomized, quadruple blind | NCT03988842 |
| Setting . | Intervention . | Study design . | ClinicalTrials.gov identifier . |
|---|---|---|---|
| Massive and submassive PE | Recombinant human prourokinase vs alteplase | Phase 2a randomized | NCT03108833 |
| High and intermediate-high risk PE with emboli in the pulmonary trunk or in the main pulmonary arteries | Surgical pulmonary embolectomy vs catheter-directed thrombolysis | Randomized, phase 2, non-inferiority | NCT03218410 |
| Acute submassive PE (radiologic extension) | Thrombin-activatable fibrinolysis inhibitor (DS-1040b) | Phase 1b, single ascending dose, randomized, double-blind, placebo-controlled | NCT02923115 |
| Normotensive right ventricular dysfunction | Percutaneous mechanical thrombectomy by indigo aspiration system | Prospective, single group | NCT03218566 |
| Intrapulmonary thrombolysis by Bashir endovascular catheter | Prospective, single group | NCT03927508 | |
| Catheter-directed thrombolysis vs ultrasound-assisted thrombolysis | Randomized controlled | NCT02758574 | |
| Diuretic vs vascular filling | Randomized controlled | NCT02531581 | |
| Supplemental oxygen added to conventional anticoagulant treatment vs standard management | Randomized, open label | NCT04003116 | |
| Nitric oxide (inhaled) vs placebo | Randomized, triple blind | NCT01939301 | |
| Sildenafil + apixaban vs apixaban | Randomized, open label | NCT02946944 | |
| Isolated subsegmental PE | No anticoagulant treatment of patients with isolated subsegmental emboli and negative serial bilateral lower extremity ultrasound | Prospective cohort | NCT01455818 |
| Hemodynamically stable symptomatic PE | HESTIA vs PESI scores for acute management concerning home treatment | Randomized, open label | NCT02811237 |
| Normotensive right ventricular dysfunction and/or increased biomarkers | LMWH for 72 hours followed by dabigatran | Prospective, single-group assignment | NCT02596555 |
| Intermediate-high risk PE | Alteplase + UFH followed by apixaban vs placebo + UFH followed by apixaban | Randomized, quadruple blind | NCT03988842 |